Gatifloxacin
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317966

CAS#: 112811-59-3 (free base)

Description: Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family that inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Gatifloxacin is a fluoroquinolone antibiotic, with potent activity against Gram-negative and Gram-positive bacteria. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin for the treatment of respiratory tract infections. Allergan produces it in eye-drop formulation under the names Zymar and Zymaxid. In many countries, gatifloxacin is also available as tablets and in various aqueous solutions for intravenous therapy.


Price and Availability

Size Price Shipping out time Quantity
1g USD 190 2 Weeks
2g USD 350 2 Weeks
5g USD 550 2 Weeks
10g USD 850 2 Weeks
20g USD 1450 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-03-29. Prices are subject to change without notice.

Gatifloxacin, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 317966
Name: Gatifloxacin
CAS#: 112811-59-3 (free base)
Chemical Formula: C19H22FN3O4
Exact Mass: 375.15943
Molecular Weight:
Elemental Analysis: Chemical Formula: C19H22FN3O4 Exact Mass: 375.15943 Molecular Weight: 375.39408 Elemental Analysis: C, 60.79; H, 5.91; F, 5.06; N, 11.19; O, 17.05


Related CAS #: 112811-59-3 (free base)   180200-66-2 (sesquihydrate)   316819-28-0 (mesyalate)   404858-36-2 (hemihydrate)    

Synonym: Gatifloxacin; Tequin; Zymar; Gatiflo; Zymaxid; AM 1155; AM-1155; BMS-206584; CG 5501; gatifloxacin; gatifloxacine; Tequin; Zymar;

IUPAC/Chemical Name: 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid

InChi Key: XUBOMFCQGDBHNK-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)

SMILES Code: CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Ruan Q, Liu Q, Sun F, Shao L, Jin J, Yu S, Ai J, Zhang B, Zhang W.
Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a
meta-analysis of randomized clinical trials. Emerg Microbes Infect. 2016 Feb
24;5:e12. doi: 10.1038/emi.2016.12. PubMed PMID: 26905025.

2: Duxfield L, Sultana R, Wang R, Englebretsen V, Deo S, Swift S, Rupenthal I,
Al-Kassas R. Development of gatifloxacin-loaded cationic polymeric nanoparticles
for ocular drug delivery. Pharm Dev Technol. 2016 Mar;21(2):172-9. doi:
10.3109/10837450.2015.1091839. Epub 2015 Oct 12. PubMed PMID: 26794936.

3: Mimouni M, Geffen N, Rosen E, Segev F. The effect of gatifloxacin 0.3% or
moxifloxacin 0.5% on corneal healing, ocular tolerability and toxicity following
pterygium surgery. Cutan Ocul Toxicol. 2016 Mar;35(1):8-12. doi:
10.3109/15569527.2014.1003266. Epub 2015 Jan 19. PubMed PMID: 25597371.

4: Kalam MA, Alshamsan A, Aljuffali IA, Mishra AK, Sultana Y. Delivery of
gatifloxacin using microemulsion as vehicle: formulation, evaluation,
transcorneal permeation and aqueous humor drug determination. Drug Deliv. 2016
Mar;23(3):896-907. doi: 10.3109/10717544.2014.920432. Epub 2014 May 28. PubMed
PMID: 24865289.

5: Arjyal A, Basnyat B, Nhan HT, Koirala S, Giri A, Joshi N, Shakya M, Pathak KR,
Mahat SP, Prajapati SP, Adhikari N, Thapa R, Merson L, Gajurel D, Lamsal K,
Lamsal D, Yadav BK, Shah G, Shrestha P, Dongol S, Karkey A, Thompson CN, Thieu
NT, Thanh DP, Baker S, Thwaites GE, Wolbers M, Dolecek C. Gatifloxacin versus
ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre,
randomised controlled trial. Lancet Infect Dis. 2016 Jan 19. pii:
S1473-3099(15)00530-7. doi: 10.1016/S1473-3099(15)00530-7. [Epub ahead of print]
PubMed PMID: 26809813.

6: Sharma N, Arora T, Jain V, Agarwal T, Jain R, Jain V, Yadav CP, Titiyal J,
Satpathy G. Gatifloxacin 0.3% Versus Fortified Tobramycin-Cefazolin in Treating
Nonperforated Bacterial Corneal Ulcers: Randomized, Controlled Trial. Cornea.
2016 Jan;35(1):56-61. doi: 10.1097/ICO.0000000000000664. PubMed PMID: 26509763.

7: Kamruzzaman M, Faruqui AN, Hossain MI, Lee SH. Spectroscopic study of the
interaction between adenosine disodium triphosphate and gatifloxacin-Al3+ complex
and its analytical application. Luminescence. 2015 Nov;30(7):1077-82. doi:
10.1002/bio.2861. Epub 2015 Feb 12. PubMed PMID: 25683636.

8: Wabaidur Sm, Alam SM, Alothman ZA, Mohsin K. Silver nanoparticles enhanced
flow injection chemiluminescence determination of gatifloxacin in pharmaceutical
formulation and spiked urine sample. Spectrochim Acta A Mol Biomol Spectrosc.
2015 Jun 5;144:170-5. doi: 10.1016/j.saa.2015.02.051. Epub 2015 Feb 21. PubMed
PMID: 25754393.

9: Lima Vaz MF, de Oliveira JV, Cassella RJ, Pacheco WF. Development of a
flow-injection analysis system with fluorescence detection for gatifloxacin
determination in organized medium. Luminescence. 2015 May;30(3):337-42. doi:
10.1002/bio.2736. Epub 2014 Jul 24. PubMed PMID: 25060163.

10: A four-month gatifloxacin-containing regimen for treating tuberculosis. N
Engl J Med. 2015 Apr 23;372(17):1677. doi: 10.1056/NEJMx150015. PubMed PMID:
25901444.

11: Kumbhar GB, Khan AM, Rampal S. Evaluation of gatifloxacin for its potential
to induce antioxidant imbalance and retinopathy in rabbits. Hum Exp Toxicol. 2015
Apr;34(4):372-9. doi: 10.1177/0960327114530743. Epub 2014 Jul 15. PubMed PMID:
25028261.

12: Zhang CJ, Lei HT, Huang XL, Liu YJ, Cai K, Xu ZL, Sun YM. Preparative
resolution of gatifloxacin enantiomers with pre-column esterification strategy
and comparing their enantioselectivity to bacteria and antibody. Biomed Environ
Sci. 2015 Feb;28(2):157-60. doi: 10.3967/bes2015.021. PubMed PMID: 25716569.

13: Ding W, Ni W, Chen H, Yuan J, Huang X, Zhang Z, Wang Y, Yu Y, Yao K.
Comparison of Drug Concentrations in Human Aqueous Humor after the Administration
of 0.3% Gatifloxacin Ophthalmic Gel, 0.3% Gatifloxacin and 0.5% Levofloxacin
Ophthalmic Solutions. Int J Med Sci. 2015 Jun 10;12(6):517-23. doi:
10.7150/ijms.11376. eCollection 2015. PubMed PMID: 26078713; PubMed Central
PMCID: PMC4466517.

14: Aljuffali IA, Kalam MA, Sultana Y, Imran A, Alshamsan A. Development and
validation of stability-indicating high performance liquid chromatography method
to analyze gatifloxacin in bulk drug and pharmaceutical preparations. Saudi Pharm
J. 2015 Jan;23(1):85-94. doi: 10.1016/j.jsps.2014.06.005. Epub 2014 Jun 28.
PubMed PMID: 25685047; PubMed Central PMCID: PMC4310989.

15: Heller W, Cruz M, Bhagat YR, De Leon JM, Felix C, Villanueva L, Hollander DA,
Jensen H. Gatifloxacin 0.5% administered twice daily for the treatment of acute
bacterial conjunctivitis in patients one year of age or older. J Ocul Pharmacol
Ther. 2014 Dec;30(10):815-22. doi: 10.1089/jop.2014.0040. PubMed PMID: 25244402.

16: Arthanari S, Mani G, Jang JH, Choi JO, Cho YH, Lee JH, Cha SE, Oh HS, Kwon
DH, Jang HT. Preparation and characterization of gatifloxacin-loaded
alginate/poly (vinyl alcohol) electrospun nanofibers. Artif Cells Nanomed
Biotechnol. 2014 Dec 15:1-6. [Epub ahead of print] PubMed PMID: 25510448.

17: Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, Odhiambo J,
Amukoye E, Bah B, Kassa F, N'Diaye A, Rustomjee R, de Jong BC, Horton J, Perronne
C, Sismanidis C, Lapujade O, Olliaro PL, Lienhardt C; OFLOTUB/Gatifloxacin for
Tuberculosis Project. A four-month gatifloxacin-containing regimen for treating
tuberculosis. N Engl J Med. 2014 Oct 23;371(17):1588-98. doi:
10.1056/NEJMoa1315817. Erratum in: N Engl J Med. 2015 Apr 23;372(17):1677. PubMed
PMID: 25337748.

18: Kłosińska-Szmurło E, Pluciński FA, Grudzień M, Betlejewska-Kielak K,
Biernacka J, Mazurek AP. Experimental and theoretical studies on the molecular
properties of ciprofloxacin, norfloxacin, pefloxacin, sparfloxacin, and
gatifloxacin in determining bioavailability. J Biol Phys. 2014 Sep;40(4):335-45.
doi: 10.1007/s10867-014-9354-z. Epub 2014 Jul 18. PubMed PMID: 25033818; PubMed
Central PMCID: PMC4119185.

19: Kanoujia J, Kushwaha PS, Saraf SA. Evaluation of gatifloxacin pluronic
micelles and development of its formulation for ocular delivery. Drug Deliv
Transl Res. 2014 Aug;4(4):334-43. doi: 10.1007/s13346-014-0194-y. PubMed PMID:
25787066.

20: Shams S, Ali B, Afzal M, Kazmi I, Al-Abbasi FA, Anwar F. Antifungal effect of
Gatifloxacin and copper ions combination. J Antibiot (Tokyo). 2014
Jul;67(7):499-504. doi: 10.1038/ja.2014.35. Epub 2014 Jun 4. PubMed PMID:
24894182.